|
Clinical and biochemical data groups in type 2 diabetes treated with 1200 IU α-tocopherol/day or placebo for 4 weeks |
||||
| α-tocopherol Group (n = 10) |
Placebo Group (n = 9) |
|||
|
|
||||
| Day 0 |
Day 29 |
Day 0 |
Day 29 |
|
|
|
||||
| Age (Y) |
62.7 (1.81) |
__ |
61.9 (1.92) |
__ |
| Diabetes duration |
11.1 (2.52) |
__ |
2.6 (0.4)a |
__ |
| BMI |
29.9 (1.2) |
__ |
29.4 (1.3) |
__ |
| WHR |
0.92 (0.026) |
__ |
0.94 (0.021) |
__ |
| Fasting plasma glucose (mmol/L) |
10.7 (0.94) |
10.2 (0.86) |
7.6 (0.39)a |
7.7 (0.41)b |
| Fasting plasma insulin (mU/L) |
49.6 (6.67) |
56.2 (9.91) |
55.5 (7.81) |
54.5 (6.87) |
| Post-GTT plasma glucose (mmol/L) |
20.2 (1.25)c |
19.1 (1.26)c |
15.1 (0.94)c |
15.0 (1.32)c |
| Post-GTT plasma insulin (mU/L) |
135 (37.1)d |
124 (31.9)d |
218 (47.7)c |
261 (87.0)d |
| HbA1c (%) |
8.4 (0.6) |
__ |
7.2 (0.3) |
__ |
| Plasma α-tocopherol (μmol/L) |
28.9 (1.82) |
66.5 (7.26)e |
24.4 (1.71) |
25.0 (1.78) |
| 8-oxoquanine fluorescence (MFI) |
462 (28.0) |
456 (19.0) |
506 (27.1) |
495 (15.2) |
|
Data shown are means (SE) a p < 0.01 placebo v α-tocopherol; b p < 0.05 placebo v α-tocopherol; c p < 0.01 Fasting v post-GTT; d p < 0.05 Fasting v post-GTT e p < 0.01 Day 0 v Day 29 | ||||
Winterbone et al. Cardiovascular Diabetology 2007 6:8 doi:10.1186/1475-2840-6-8 |
||||